A detailed history of M&R Capital Management Inc transactions in Amgen Inc stock. As of the latest transaction made, M&R Capital Management Inc holds 654 shares of AMGN stock, worth $211,026. This represents 0.05% of its overall portfolio holdings.

Number of Shares
654
Previous 652 0.31%
Holding current value
$211,026
Previous $185,000 10.27%
% of portfolio
0.05%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 02, 2024

BUY
$262.75 - $319.31 $525 - $638
2 Added 0.31%
654 $204,000
Q1 2024

Apr 02, 2024

SELL
$268.87 - $324.56 $20,971 - $25,315
-78 Reduced 10.68%
652 $185,000
Q4 2023

Jan 02, 2024

BUY
$255.7 - $288.46 $32,473 - $36,634
127 Added 21.06%
730 $210,000
Q3 2023

Oct 10, 2023

BUY
$218.65 - $271.46 $437 - $542
2 Added 0.33%
603 $162,000
Q2 2023

Jul 05, 2023

SELL
$214.27 - $253.37 $101,992 - $120,604
-476 Reduced 44.2%
601 $133,000
Q1 2023

Apr 03, 2023

SELL
$225.79 - $275.2 $9,257 - $11,283
-41 Reduced 3.67%
1,077 $260,000
Q4 2022

Jan 11, 2023

SELL
$229.03 - $291.01 $61,609 - $78,281
-269 Reduced 19.39%
1,118 $0
Q3 2022

Oct 03, 2022

BUY
$224.46 - $253.15 $131,309 - $148,092
585 Added 72.94%
1,387 $312,000
Q2 2022

Jul 05, 2022

BUY
$230.71 - $256.74 $56,523 - $62,901
245 Added 43.99%
802 $195,000
Q1 2022

Apr 04, 2022

BUY
$219.27 - $242.57 $66,219 - $73,256
302 Added 118.43%
557 $134,000
Q4 2021

Jan 07, 2022

SELL
$198.88 - $227.6 $44,748 - $51,210
-225 Reduced 46.88%
255 $57,000
Q3 2021

Oct 05, 2021

SELL
$212.27 - $248.7 $554,024 - $649,107
-2,610 Reduced 84.47%
480 $102,000
Q2 2021

Jul 02, 2021

SELL
$233.58 - $259.14 $19,854 - $22,026
-85 Reduced 2.68%
3,090 $753,000
Q1 2021

Apr 01, 2021

BUY
$221.91 - $258.6 $31,067 - $36,204
140 Added 4.61%
3,175 $789,000
Q4 2020

Jan 05, 2021

BUY
$216.38 - $257.67 $27,047 - $32,208
125 Added 4.3%
3,035 $697,000
Q3 2020

Oct 01, 2020

BUY
$234.65 - $260.95 $22,291 - $24,790
95 Added 3.37%
2,910 $739,000
Q2 2020

Jul 01, 2020

SELL
$197.81 - $242.74 $296,715 - $364,110
-1,500 Reduced 34.76%
2,815 $663,000
Q1 2020

Apr 02, 2020

BUY
$182.24 - $241.7 $78,363 - $103,931
430 Added 11.07%
4,315 $874,000
Q4 2019

Jan 07, 2020

SELL
$189.21 - $243.2 $38,220 - $49,126
-202 Reduced 4.94%
3,885 $936,000
Q3 2019

Oct 02, 2019

SELL
$174.11 - $208.62 $365,631 - $438,102
-2,100 Reduced 33.94%
4,087 $790,000
Q2 2019

Jul 24, 2019

SELL
$166.7 - $195.41 $20,837 - $24,426
-125 Reduced 1.98%
6,187 $1.14 Million
Q1 2019

Apr 29, 2019

BUY
$180.87 - $203.88 $18,087 - $20,388
100 Added 1.61%
6,312 $1.15 Million
Q4 2018

Feb 08, 2019

BUY
$178.4 - $208.25 $51,200 - $59,767
287 Added 4.84%
6,212 $1.21 Million
Q3 2018

Nov 09, 2018

SELL
$185.29 - $208.89 $55,587 - $62,666
-300 Reduced 4.82%
5,925 $1.23 Million
Q2 2018

Aug 08, 2018

BUY
$166.05 - $186.51 $166,880 - $187,442
1,005 Added 19.25%
6,225 $1.15 Million
Q1 2018

May 11, 2018

BUY
$169.43 - $198.0 $17,790 - $20,790
105 Added 2.05%
5,220 $889,000
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $56,544 - $63,177
335 Added 7.01%
5,115 $889,000
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $16,729 - $19,100
100 Added 2.14%
4,780 $891,000
Q2 2017

Aug 15, 2017

BUY
N/A
4,680
4,680 $792,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $173B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track M&R Capital Management Inc Portfolio

Follow M&R Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&R Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on M&R Capital Management Inc with notifications on news.